151 related articles for article (PubMed ID: 23021201)
1. Trajectory of fatigue severity in natalizumab treated multiple sclerosis patients.
Yildiz M; Tettenborn B; Borgwardt S
Clin Neurol Neurosurg; 2013 Jul; 115(7):902-3. PubMed ID: 23021201
[TBL] [Abstract][Full Text] [Related]
2. Multiple sclerosis associated fatigue during natalizumab treatment.
Putzki N; Yaldizli O; Tettenborn B; Diener HC
J Neurol Sci; 2009 Oct; 285(1-2):109-13. PubMed ID: 19560168
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
4. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
[TBL] [Abstract][Full Text] [Related]
5. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Phillips JT; Giovannoni G; Lublin FD; O'Connor PW; Polman CH; Willoughby E; Aschenbach W; Pace A; Hyde R; Munschauer FE
Mult Scler; 2011 Aug; 17(8):970-9. PubMed ID: 21421809
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
Lublin FD; Cutter G; Giovannoni G; Pace A; Campbell NR; Belachew S
Mult Scler Relat Disord; 2014 Nov; 3(6):705-11. PubMed ID: 25891549
[TBL] [Abstract][Full Text] [Related]
7. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
[TBL] [Abstract][Full Text] [Related]
8. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
[TBL] [Abstract][Full Text] [Related]
9. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
[TBL] [Abstract][Full Text] [Related]
11. The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis.
Sayao AL; Bueno AM; Devonshire V; Tremlett H;
Mult Scler; 2011 Nov; 17(11):1375-83. PubMed ID: 21677023
[TBL] [Abstract][Full Text] [Related]
12. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis.
Calabrese M; Rinaldi F; Grossi P; Mattisi I; Bernardi V; Favaretto A; Perini P; Gallo P
Mult Scler; 2010 Oct; 16(10):1220-8. PubMed ID: 20670981
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.
Fernández-Megía MJ; Casanova B; Magraner MJ; Font-Noguera I; Poveda-Andrés JL
Farm Hosp; 2011; 35(2):75-9. PubMed ID: 20685144
[TBL] [Abstract][Full Text] [Related]
14. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of Bio-Electromagnetic-Energy Regulation therapy on fatigue in patients with multiple sclerosis.
Haase R; Piatkowski J; Ziemssen T
Altern Ther Health Med; 2011; 17(6):22-8. PubMed ID: 22314716
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
17. Cognitive impairment has a strong relation to nonsomatic symptoms of depression in relapsing-remitting multiple sclerosis.
Sundgren M; Maurex L; Wahlin Å; Piehl F; Brismar T
Arch Clin Neuropsychol; 2013 Mar; 28(2):144-55. PubMed ID: 23291310
[TBL] [Abstract][Full Text] [Related]
18. Effect of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial.
Piatkowski J; Kern S; Ziemssen T
J Altern Complement Med; 2009 May; 15(5):507-11. PubMed ID: 19422286
[TBL] [Abstract][Full Text] [Related]
19. A randomized crossover study of bee sting therapy for multiple sclerosis.
Wesselius T; Heersema DJ; Mostert JP; Heerings M; Admiraal-Behloul F; Talebian A; van Buchem MA; De Keyser J
Neurology; 2005 Dec; 65(11):1764-8. PubMed ID: 16221950
[TBL] [Abstract][Full Text] [Related]
20. Stimulated peripheral production of interferon-gamma is related to fatigue and depression in multiple sclerosis.
Pokryszko-Dragan A; Frydecka I; Kosmaczewska A; Ciszak L; Bilińska M; Gruszka E; Podemski R; Frydecka D
Clin Neurol Neurosurg; 2012 Oct; 114(8):1153-8. PubMed ID: 22425464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
